Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Feature
  • Published:

Public biotechnology 2005—the numbers

Although investors remained cautious of public biotech companies in 2005, acquisitions and research partnerships were on the up.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Global biotech initial public offerings.
Figure 2: Public biotech companies by geographical location.
Figure 3: Public biotech revenue, R&D spending and profit by market cap.
Figure 4: Global biotech industry financing.
Figure 5: Public biotech companies by sector of application.

Author information

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lähteenmäki, R., Lawrence, S. Public biotechnology 2005—the numbers. Nat Biotechnol 24, 625–634 (2006). https://doi.org/10.1038/nbt0606-625

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0606-625

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing